These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 35326677)

  • 21. Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
    Han Y; Zhi WH; Xu F; Zhang CB; Huang XQ; Luo JF
    World J Gastroenterol; 2021 May; 27(19):2415-2433. PubMed ID: 34040331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update.
    Kudo M
    Liver Cancer; 2020 Dec; 9(6):640-662. PubMed ID: 33442538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination Antiangiogenic and Immunotherapy for Advanced Hepatocellular Carcinoma: Evidence to Date.
    Raybould AL; Sanoff H
    J Hepatocell Carcinoma; 2020; 7():133-142. PubMed ID: 32984090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Evolving Landscape of Checkpoint Inhibitor Combination Therapy in the Treatment of Advanced Hepatocellular Carcinoma.
    Liu L; Qin S; Zhang Y
    Target Oncol; 2021 Mar; 16(2):153-163. PubMed ID: 33528759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic therapy for hepatocellular carcinoma: current status and future perspectives.
    Furuse J; Ueno M; Ikeda M
    Jpn J Clin Oncol; 2021 Aug; 51(9):1363-1371. PubMed ID: 34258616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease.
    Perera S; Kelly D; O'Kane GM
    Curr Oncol; 2020 Nov; 27(Suppl 3):S165-S172. PubMed ID: 33343210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients.
    Ziogas IA; Evangeliou AP; Giannis D; Hayat MH; Mylonas KS; Tohme S; Geller DA; Elias N; Goyal L; Tsoulfas G
    Oncologist; 2021 Jun; 26(6):e1036-e1049. PubMed ID: 33314549
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review article: new therapeutic interventions for advanced hepatocellular carcinoma.
    Bangaru S; Marrero JA; Singal AG
    Aliment Pharmacol Ther; 2020 Jan; 51(1):78-89. PubMed ID: 31747082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trends in the treatment of advanced hepatocellular carcinoma: immune checkpoint blockade immunotherapy and related combination therapies.
    Cheng H; Sun G; Chen H; Li Y; Han Z; Li Y; Zhang P; Yang L; Li Y
    Am J Cancer Res; 2019; 9(8):1536-1545. PubMed ID: 31497341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment.
    Liu ZL; Liu JH; Staiculescu D; Chen J
    Ther Adv Med Oncol; 2021; 13():17588359211018026. PubMed ID: 34104226
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives.
    Federico P; Petrillo A; Giordano P; Bosso D; Fabbrocini A; Ottaviano M; Rosanova M; Silvestri A; Tufo A; Cozzolino A; Daniele B
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33080958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatocellular Carcinoma Immunotherapy.
    Sperandio RC; Pestana RC; Miyamura BV; Kaseb AO
    Annu Rev Med; 2022 Jan; 73():267-278. PubMed ID: 34606324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma.
    Chan LL; Chan SL
    Expert Opin Emerg Drugs; 2021 Mar; 26(1):39-52. PubMed ID: 33724135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.
    Melosky B; Juergens R; Hirsh V; McLeod D; Leighl N; Tsao MS; Card PB; Chu Q
    Oncologist; 2020 Jan; 25(1):64-77. PubMed ID: 31138727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait.
    Rizzo A; Ricci AD; Brandi G
    Immunotherapy; 2021 Jun; 13(8):637-644. PubMed ID: 33820447
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects.
    D'Alessio A; Rimassa L; Cortellini A; Pinato DJ
    J Hepatocell Carcinoma; 2021; 8():887-897. PubMed ID: 34386437
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma.
    Rizzo A; Brandi G
    Cancer Treat Res Commun; 2021; 27():100328. PubMed ID: 33549983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic Management of Advanced Hepatocellular Carcinoma: An Updated Review.
    Falette Puisieux M; Pellat A; Assaf A; Ginestet C; Brezault C; Dhooge M; Soyer P; Coriat R
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35625962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How Immunotherapy Has Changed the Continuum of Care in Hepatocellular Carcinoma.
    Martini G; Ciardiello D; Paragliola F; Nacca V; Santaniello W; Urraro F; Stanzione M; Niosi M; Dallio M; Federico A; Selvaggi F; Della Corte CM; Napolitano S; Ciardiello F; Martinelli E
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic targeted and immunotherapy for advanced hepatocellular carcinoma.
    Cersosimo RJ
    Am J Health Syst Pharm; 2021 Jan; 78(3):187-202. PubMed ID: 33211092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.